Cannvas Committed to Enhancing Cannabis Experience Through Technology Ancillary Cannabis Market Generates Significant Economic Benefit
Cannvas MedTech Inc. (“Cannvas” or the “Company”) (CSE:MTEC), a leading business technology company within the cannabis health sciences space, is pleased to announce that it is committed to enhancing the medical and recreational cannabis health and wellness experience through advanced technology through an inventive online portal. The Company is launching a patient-centric life science learning platform that will allow users to interact on a global basis to research and gain valuable knowledge on how best to use cannabis to improve their own health and wellness.
Cannvas is taking an innovative approach to use advanced technology and data to augment the growth phenomenon experienced by the cannabis leaf markets. Cannabis market studies, conducted by Deloitte on Canada’s soon to be legal recreational market, predict that sales could reach as much as $7 billion in 2019, and revenue generated from future ancillary activities could boost the economic impact to more than triple that amount. By being first-to-market and harnessing the power of data and design to build customer-centric initiatives in the medical cannabis and health sciences sectors, the Cannvas is positioned for long term success.
Cannvas offers design and execution expertise across advanced technology, data aggregation and analysis, blockchain, and creative disciplines.
About Cannvas MedTech Inc.
Cannvas MedTech is a leading business technology company within the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.
For additional information:
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Company’s future plans, objectives or goals, including words to the effect that the Company or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.
SOURCE Cannvas MedTech Inc.
Both locations expand access to the state’s widest-ranging inventory of medical cannabis products for Central Florida patients
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of two brand-new Central Florida dispensaries. The new Clearwater and Tampa locations mark the Company’s 81 st and 82 nd nationwide, respectively, widening patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Philip Young, CEO and Director of Lobe, stated, “We are honored to welcome Bart to our Advisory Board. His first-hand experience on and off the field are tremendously valuable as we continue our research involving mild traumatic brain injuries and PTSD. These issues are prevalent in contact sports and we believe that athletes will play a prominent role in the continued acceptance of psychedelic medicines as legitimate treatment. We look forward to working with Bart as we seek to forge long-term strategic relationships.”
HempFusion Wellness Submits Novel Foods Dossier to the United Kingdom’s Regulatory Food Safety Agency
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that it has submitted its dossier to the United Kingdom’s Regulatory Food Safety Agency (the “FSA”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210303005322/en/